A PHASE II, MULTI-CENTRE, OPEN LABEL STUDY OF MELPHALAN, PREDNISONE, THALIDOMIDE AND BORTEZOMIB IN ADVANCED AND REFRACTORY MULTIPLE MYELOMA PATIENTS.
- Conditions
- ADVANCED AND REFRACTORY MULTIPLE MYELOMA PATIENTS.MedDRA version: 9.1Level: LLTClassification code 10028228Term: Multiple myeloma
- Registration Number
- EUCTR2004-000565-34-IT
- Lead Sponsor
- AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: DETERMINARE SE L'ASSOCIAZIONE MPTV COME TERAPIA DI SALVATAGGIO E' SICURA E DA BENEFICI NEI PAZIENTI CON MIELOMA AVANZATO-REFRATTARIO. <br><br>;Secondary Objective: DETERMINARE SE LE RISPOSTE OTTENUTE CON IL TRATTAMENTO MPTV SONO ASSOCIATE AD UN PROLUNGAMENTO DELLA SOPRAVVIVENZA LIBERA DA MALATTIA, COMPARATO AI PAZIENTI NON RESPONSIVI. <br>;Primary end point(s): DETERMINAZIONE DEL TASSO DI RISPOSTA IN ACCORDO CON I CRITERI EGBMT. <br><br>
- Secondary Outcome Measures
Name Time Method